Artificial kidney project led by Roy cited at White House panel

Speaking on a White House panel discussing President Obama's just-released Bioeconomy Blueprint, UCSF Vice Chancellor for Research Keith Yamamoto, PhD, cited the implantable bioartificial kidney project led by UCSF bioengineer Shuvo Roy, PhD, as a prime example of biomedical collaboration with potentially major social and economic impact.

Yamamoto, who was part of the panel of academic and industry representatives convened on April 26, 2012, noted that the bioartificial kidney, targeted for clinical trials in 2017, "is expected to dramatically improve the quality of life and survival of patients with end stage renal disease."

Roy, a faculty member in the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine, is leading the project that brings together 40 researchers in nine laboratories nationwide.

The project was recently selected to undergo accelerated collaborative review under a pilot project at the U.S. Food and Drug Administration.

Yamamoto noted the health and economic impact of end stage renal disease, which affects 1% of the U.S. population but consumes 7% of the Medicare budget. The national cost of treating end stage renal disease is $40 billion, of which $30 billion is paid by Medicare. Meanwhile, kidney transplants meet only a fraction of the demand and hundreds of thousands of patients rely on in-clinic dialysis treatment, with "severely compromised" quality of life and only 35% of patients surviving after five years.

Video of White House panel

UCSF Vice Chancellor Keith Yamamoto, PhD, speaks at the 35-minute mark:

The Bioeconomy Blueprint Panel

More information


School of Pharmacy, Department of Bioengineering and Therapeutic Sciences, PharmD Degree Program, QBC, PSPG

About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.